x
Filter:
Filters applied
- Reviews
- Alisi, AnnaRemove Alisi, Anna filter
Publication Date
Please choose a date range between 2013 and 2021.
Reviews
2 Results
- Review
The application of artificial intelligence in hepatology: A systematic review
Digestive and Liver DiseaseVol. 54Issue 3p299–308Published online: July 12, 2021- Clara Balsano
- Anna Alisi
- Maurizia R. Brunetto
- Pietro Invernizzi
- Patrizia Burra
- Fabio Piscaglia
- and others
Cited in Scopus: 5The integration of human and artificial intelligence (AI) in medicine has only recently begun but it has already become obvious that intelligent systems can dramatically improve the management of liver diseases. Big data made it possible to envisage transformative developments of the use of AI for diagnosing, predicting prognosis and treating liver diseases, but there is still a lot of work to do. If we want to achieve the 21st century digital revolution, there is an urgent need for specific national and international rules, and to adhere to bioethical parameters when collecting data. - Review Article
Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: An input for novel therapies
Digestive and Liver DiseaseVol. 45Issue 7p543–551Published in issue: July, 2013- Otilia E. Frasinariu
- Sara Ceccarelli
- Anna Alisi
- Evelina Moraru
- Valerio Nobili
Cited in Scopus: 77Non-alcoholic fatty liver disease is a multifactorial condition, ranging from simple steatosis to non-alcoholic steatohepatitis with or without fibrosis. In non-alcoholic fatty liver disease, alteration of gut microbiota and increased intestinal permeability increase exposure of the liver to gut-derived bacterial products: lipopolysaccharides and unmethylated CpG DNA. These products stimulate innate immune receptors, namely Toll-like receptors, which activate signalling pathways involved in liver inflammation and fibrogenesis.